Bristol-Myers Squibb Company logo
Bristol-Myers Squibb Company (BMY)
Compare

Bristol-Myers Squibb Company (BMY) Earnings Per Share (EPS): 3.56

Is Bristol-Myers Squibb Company’s earnings per share (EPS) high or low?

Bristol-Myers Squibb Company's earnings per share (EPS) of 3.56 is 321% above its 5-year average of 0.84, near the high end of its 5-year range (-4.41–3.88).

As of Tuesday, June 16, 2026. 849.47% above its 12-month average of -0.48.

BMY Earnings Per Share (EPS) Chart

BMY Earnings Per Share (EPS)
3.46+178.46% 1Y
Zoom

BMY Average Earnings Per Share (EPS) Chart

BMY Current vs Average Earnings Per Share (EPS) Chart

BMY Earnings Per Share (EPS) Metrics

EARNINGS PER SHARE (EPS)

3.56

EARNINGS PER SHARE (EPS) AVG TTM

-0.48

EARNINGS PER SHARE (EPS) AVG 3Y

1.47

EARNINGS PER SHARE (EPS) AVG 5Y

0.84

EARNINGS PER SHARE (EPS) AVG 10Y

1.31

EARNINGS PER SHARE (EPS) AVG 15Y

2.19

EARNINGS PER SHARE (EPS) AVG 20Y

2.22

CURRENT VS TTM AVG

+849.47%

CURRENT VS 3Y AVG

+141.36%

CURRENT VS 5Y AVG

+321.30%

CURRENT VS 10Y AVG

+172.51%

CURRENT VS 15Y AVG

+62.40%

CURRENT VS 20Y AVG

+60.40%

BMY Competitors' Earnings Per Share (EPS)

NAMEMARKET CAPEARNINGS PER SHARE (EPS)TTM3Y5Y
Bristol-Myers Squibb Company (BMY)$114.38B3.56-0.481.470.84
Vertex Pharmaceuticals Incorporated (VRTX)vs ›$113.82B16.866.6910.109.99
Stryker Corporation (SYK)vs ›$119.06B8.648.187.736.75
Medtronic plc (MDT)vs ›$104.05B3.733.693.253.23
CVS Health Corporation (CVS)vs ›$127.54B2.272.533.714.39
Danaher Corporation (DHR)vs ›$128.72B5.175.206.666.73
HCA Healthcare, Inc. (HCA)vs ›$88.05B29.0825.4522.3920.36
Elevance Health Inc. (ELV)vs ›$86.74B23.5125.4925.2324.07
Intuitive Surgical, Inc. (ISRG)vs ›$148.26B8.257.275.845.20
Pfizer Inc. (PFE)vs ›$148.76B1.311.392.192.39

EPS Comparison

Trailing EPS (TTM)

$3.56

Forward EPS (Est.)

$6.14

P/E Ratio

15.8

Formula: EPS = Net Income / Weighted Average Shares Outstanding

Why EPS matters:

  • Directly impacts stock valuation through P/E ratio
  • Used to calculate dividend coverage and payout ratios
  • Enables comparison across companies of different sizes
  • Growth in EPS often correlates with stock price appreciation

Bristol-Myers Squibb Company Earnings Per Share (EPS) Formula & Definition

EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Bristol-Myers Squibb Company Earnings Per Share (EPS) FAQ

What is the earnings per share (EPS) for Bristol-Myers Squibb Company (BMY)?
The earnings per share (EPS) for BMY stock is 3.56.
Is Bristol-Myers Squibb Company's earnings per share (EPS) high or low?
Bristol-Myers Squibb Company's earnings per share (EPS) of 3.56 is 321% above its 5-year average of 0.84, near the high end of its 5-year range (-4.41–3.88).
What is the TTM average earnings per share (EPS) for Bristol-Myers Squibb Company (BMY)?
The TTM average earnings per share (EPS) for BMY stock is -0.48.
What is the 3Y average earnings per share (EPS) for Bristol-Myers Squibb Company (BMY)?
The 3Y average earnings per share (EPS) for BMY stock is 1.47.
What is the 5Y average earnings per share (EPS) for Bristol-Myers Squibb Company (BMY)?
The 5Y average earnings per share (EPS) for BMY stock is 0.84.
What is the 10Y average earnings per share (EPS) for Bristol-Myers Squibb Company (BMY)?
The 10Y average earnings per share (EPS) for BMY stock is 1.31.
What is the 15Y average earnings per share (EPS) for Bristol-Myers Squibb Company (BMY)?
The 15Y average earnings per share (EPS) for BMY stock is 2.19.
What is the 20Y average earnings per share (EPS) for Bristol-Myers Squibb Company (BMY)?
The 20Y average earnings per share (EPS) for BMY stock is 2.22.

Bristol-Myers Squibb Company Earnings Per Share (EPS) History

DATEEARNINGS PER SHARE (EPS)
2025-12-313.46
2024-12-31-4.41
2023-12-313.88
2022-12-312.97
2021-12-313.15
2020-12-31-3.98
2019-12-312.02
2018-12-313.03
2017-12-310.61
2016-12-312.67
2015-12-310.97
2014-12-311.21
2013-12-311.56
2012-12-311.17
2011-12-312.18
2010-12-311.81
2009-12-315.38
2008-12-312.65
2007-12-311.10
2006-12-310.81
2005-12-311.54
2004-12-311.23
2003-12-311.60
2002-12-311.03
2001-12-312.70
2000-12-312.40
1999-12-312.10
1998-12-311.58
1997-12-311.61
1996-12-311.42

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ
34,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner